Kaiser Family Foundation December 7, 2022
Jennifer Kates, Cynthia Cox, Josh Michaud

The federal government has spent more than $30 billion1 on COVID-19 vaccines, including the new bivalent boosters, incentivizing their development, guaranteeing a market, and ensuring that these vaccines would be provided free of charge to the U.S. population. However, the Biden Administration has announced that it no longer has funding, absent further Congressional action, to make further purchases and has begun to prepare for the transition of COVID-19 vaccines to the commercial market. This means that manufacturers will be negotiating prices directly with insurers and purchasers, not just the federal government, and prices are expected to rise. Elsewhere, we have analyzed the implications of commercialization for access to and coverage of COVID-19 vaccines, finding that most, but not all, people...

Today's Sponsors


Today's Sponsor

Health Edge

Topics: Biotechnology, Govt Agencies, Healthcare System, Patient / Consumer, Pharma / Biotech, Provider, Public Health / COVID
U.S. plans to stop buying Covid shots for the public this fall. Here's what that means
Opinion: Public health layoffs and tech layoffs: a world of difference
Getting Government To Work For Public Health
6 states where COVID-19 admissions are rising
Why the mpox outbreak only lasted 6 months: 3 notes for future infection crises

Share This Article